Lys29-linkage of ASK1 by Skp1−Cullin 1−Fbxo21 ubiquitin ligase complex is required for antiviral innate response

  1. Zhou Yu
  2. Taoyong Chen  Is a corresponding author
  3. Xuelian Li
  4. Mingjin Yang
  5. Songqing Tang
  6. Xuhui Zhu
  7. Yan Gu
  8. Xiaoping Su
  9. Meng Xia
  10. Weihua Li
  11. Xuemin Zhang
  12. Qingqing Wang
  13. Xuetao Cao
  14. Jianli Wang
  1. Institute of Immunology, China
  2. National Key Laboratory of Medical Immunology and Institute of Immunology, China
  3. National Key Laboratory of Medical Molecular Biology and Department of Immunology, China
  4. Institute of Basic Medical Sciences, China
  5. Zhejiang University School of Medicine, China

Abstract

Protein ubiquitination regulated by ubiquitin ligases plays important roles in innate immunity. However, key regulators of ubiquitination during innate response and roles of new types of ubiquitination (apart from Lys48- and Lys63-linkage) in control of innate signaling have not been clearly understood. Here we report that F-box only protein Fbxo21, a functionally unknown component of SCF (Skp1-Cul1-F-box protein) complex, facilitates Lys29-linkage and activation of ASK1 (apoptosis signal-regulating kinase 1), and promotes type I interferon production upon viral infection. Fbxo21 deficiency in mice cells impairs virus-induced Lys29-linkage and activation of ASK1, attenuates c-Jun N-terminal kinase (JNK) and p38 signaling pathway, and decreases the production of proinflammatory cytokines and type I interferon, resulting in reduced antiviral innate response and enhanced virus replication. Therefore Fbxo21 is required for ASK1 activation via Lys29-linkage of ASK1 during antiviral innate response, providing mechanistic insights into non-proteolytic roles of SCF complex in innate immune response.

Article and author information

Author details

  1. Zhou Yu

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  2. Taoyong Chen

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    For correspondence
    chenty@immunol.org
    Competing interests
    No competing interests declared.
  3. Xuelian Li

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  4. Mingjin Yang

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  5. Songqing Tang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  6. Xuhui Zhu

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  7. Yan Gu

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  8. Xiaoping Su

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  9. Meng Xia

    Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, National Key Laboratory of Medical Molecular Biology and Department of Immunology, Beijing, China
    Competing interests
    No competing interests declared.
  10. Weihua Li

    National Center of Biomedical Analysis, Institute of Basic Medical Sciences, Beijing, China
    Competing interests
    No competing interests declared.
  11. Xuemin Zhang

    National Center of Biomedical Analysis, Institute of Basic Medical Sciences, Beijing, China
    Competing interests
    No competing interests declared.
  12. Qingqing Wang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  13. Xuetao Cao

    National Key Laboratory of Medical Immunology and Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China
    Competing interests
    Xuetao Cao, Reviewing editor, eLife.
  14. Jianli Wang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and was approved by the Scientific Investigation Board of Second Military Medical University, Shanghai (Case No. SMMU-2015-0067).

Copyright

© 2016, Yu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,515
    views
  • 709
    downloads
  • 47
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhou Yu
  2. Taoyong Chen
  3. Xuelian Li
  4. Mingjin Yang
  5. Songqing Tang
  6. Xuhui Zhu
  7. Yan Gu
  8. Xiaoping Su
  9. Meng Xia
  10. Weihua Li
  11. Xuemin Zhang
  12. Qingqing Wang
  13. Xuetao Cao
  14. Jianli Wang
(2016)
Lys29-linkage of ASK1 by Skp1−Cullin 1−Fbxo21 ubiquitin ligase complex is required for antiviral innate response
eLife 5:e14087.
https://doi.org/10.7554/eLife.14087

Share this article

https://doi.org/10.7554/eLife.14087

Further reading

    1. Immunology and Inflammation
    Chan-Su Park, Jian Guan ... Scheherazade Sadegh-Nasseri
    Research Article

    The fate of developing T cells is determined by the strength of T cell receptor (TCR) signal they receive in the thymus. This process is finely regulated through the tuning of positive and negative regulators in thymocytes. The Family with sequence similarity 49 member B (Fam49b) protein is a newly discovered negative regulator of TCR signaling that has been shown to suppress Rac-1 activity in vitro in cultured T cell lines. However, the contribution of Fam49b to the thymic development of T cells is unknown. To investigate this important issue, we generated a novel mouse line deficient in Fam49b (Fam49b-KO). We observed that Fam49b-KO double positive (DP) thymocytes underwent excessive negative selection, whereas the positive selection stage was unaffected. Fam49b deficiency impaired the survival of single positive thymocytes and peripheral T cells. This altered development process resulted in significant reductions in CD4 and CD8 single-positive thymocytes as well as peripheral T cells. Interestingly, a large proportion of the TCRγδ+ and CD8αα+TCRαβ+ gut intraepithelial T lymphocytes were absent in Fam49b-KO mice. Our results demonstrate that Fam49b dampens thymocytes TCR signaling in order to escape negative selection during development, uncovering the function of Fam49b as a critical regulator of the selection process to ensure normal thymocyte development and peripheral T cells survival.

    1. Cell Biology
    2. Immunology and Inflammation
    Richard A Kahn, Harvinder Virk ... Skye Longworth
    Feature Article

    Antibodies are used in many areas of biomedical and clinical research, but many of these antibodies have not been adequately characterized, which casts doubt on the results reported in many scientific papers. This problem is compounded by a lack of suitable control experiments in many studies. In this article we review the history of the ‘antibody characterization crisis’, and we document efforts and initiatives to address the problem, notably for antibodies that target human proteins. We also present recommendations for a range of stakeholders – researchers, universities, journals, antibody vendors and repositories, scientific societies and funders – to increase the reproducibility of studies that rely on antibodies.